EFFECT OF INCREASED SERUM SULPHHYDRYL CONTENT ON TITRE OF RHEUMATOID FACTOR*

BY

ISRAELI A. JAFFE AND PARVIN MERRYMAN

Department of Medicine, New York Medical College, New York, N.Y.

The prolonged administration of the sulphhydryl compound penicillamine to rheumatoid arthritis patients results in a fall in the titre of rheumatoid factor (Jaffe, 1963). The mechanism by which the drug produces this effect is unknown, though it does not appear to be by intravascular depolymerization of macroglobulins (Jaffe, 1964) or by immunosuppression by pyridoxine antagonism (Jaffe, 1965). It has been reported that the serum sulphhydryl content is abnormally low in patients with rheumatoid arthritis, and that the deficiency in protein sulphhydryl groups may be responsible for the formation of abnormal immunoglobulins including rheumatoid factor (Lorber, Pearson, Meredith, and Gantz-Mandell, 1964). The restoration of the depressed serum sulphhydryl content by penicillamine was suggested as a possible mechanism to explain the fall in rheumatoid factor titre and clinical improvement observed following a course of treatment with this drug (Lorber, 1966). The purpose of this study was to test that hypothesis by correlating the changes in rheumatoid factor and the serum sulphhydryl content induced by three sulphhydryl compounds systemically administered to two patients with rheumatoid arthritis.

Methods

The two patients studied had active long-standing rheumatoid arthritis and were in anatomical Stage IV by the criteria of The American Rheumatism Association (Steinbrocker, Traeger, and Batterman, 1949). They were hospitalized throughout the entire period of the investigation. Blood specimens were obtained weekly in the fasting state for determination of serum sulphhydryl content and rheumatoid factor. The serum sulphhydryl determinations were made within 4 hours of venepuncture, by a modified amperometric titration using a Sargent-XV polarograph (Lorber and others, 1964). Serum samples from each treatment period were subjected to ultrafiltration for determination of the sulphhydryl content of the filtrates. Rheumatoid factor was measured immunochemically by the quantitative precipitin technique (Franklin and Kunkel, 1957; Edelman, Kunkel, and Franklin, 1958), in which increasing amounts of heat-aggregated human gamma globulin were added to the test serum and the protein content of the resulting precipitates was determined. The serum of Patient 2 was diluted 1:2 with saline in order to obtain a suitable curve as evidenced by a fall in the protein content of the precipitate in the region of antigen excess. The drugs employed in the study were D-penicillamine, N-acetyl D-penicillamine, and mercaptoethylamine (cysteamine) (Fig. 1). All drugs were given in four divided doses, after meals and at bedtime. The daily dosage of D-penicillamine and N-acetyl D-penicillamine was 2-0 g., and that of mercaptoethylamine 2-4 g. Each period of study lasted approximately 16 weeks. The patients were carefully observed clinically and by appropriate laboratory tests for signs of drug toxicity.

\[ \text{HS-C-CH-COOH} \]

Penicillamine

\[ \text{HS-C-CH-COOH} \]

N-Acetyl Penicillamine

\[ \text{HS-CH_2-CH_2NH_2} \]

Mercaptoethylamine

Fig. 1.—Structural formulae of the three sulphhydryl compounds employed in the study.

Results

The serum sulphhydryl content in normal subjects was 400-600 μM/litre, in agreement with the values that had previously been reported (Lorber and others, 1964). The reproducibility of sulphhydryl determinations on the same specimen was within 5 per cent. Ultrafiltration of sera obtained during each treatment period showed virtually no free sulphhydryl groups in the filtrates (less than 4 μM/1).
SERUM SULPHYDRYL AND RHEUMATOID FACTOR

As shown in the Table, both patients had a low serum sulphydryl content before the administration of one of the thiol compounds, and the values rose during each course. The magnitude of the increase and the rate at which it occurred was similar for each drug, and once the maximum concentration was achieved it remained relatively stable (Table).

The relation between the serum sulphydryl content and the rheumatoid factor titre at the beginning and end of each period is shown in Figs 2 and 3. Although the increase in serum sulphydryl content was remarkably constant for each course of thiol compound administered, the titre of rheumatoid factor fell only after D-penicillamine treatment.

No significant clinical changes in these patients with end-stage disease were observed with any course, regardless of the presence or absence of reductions in titre.

### Table

#### SERUM SULPHYDRYL CONCENTRATIONS (µM/L) DURING COURSES OF THIOL ADMINISTRATION

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Course No.</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>296</td>
<td>292</td>
<td>290</td>
<td>300</td>
<td>300</td>
<td>324</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>300</td>
<td>280</td>
<td>310</td>
<td>300</td>
<td>340</td>
<td>344</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>300</td>
<td>312</td>
<td>310</td>
<td>320</td>
<td>390</td>
<td>360</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>336</td>
<td>320</td>
<td>340</td>
<td>352</td>
<td>380</td>
<td>396</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>360</td>
<td>340</td>
<td>348</td>
<td>360</td>
<td>372</td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>370</td>
<td>370</td>
<td>370</td>
<td>364</td>
<td>398</td>
<td>338</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>352</td>
<td>360</td>
<td>360</td>
<td>368</td>
<td>404</td>
<td>392</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>360</td>
<td>368</td>
<td>360</td>
<td>370</td>
<td>404</td>
<td>408</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>360</td>
<td>368</td>
<td>360</td>
<td>370</td>
<td>404</td>
<td>408</td>
</tr>
</tbody>
</table>

Fig. 2.—Effect of the three sulphydryl compounds on the titre of rheumatoid factor in the same patient. The height of the curve indicates the amount of precipitable rheumatoid factor after the addition of increasing amounts of aggregated gamma globulin to each serum specimen. Only courses 2 and 4, when D-penicillamine was given, resulted in a fall in titre. Note that the maximum sulphydryl concentrations produced by all drugs was virtually identical.
ANNALS OF THE RHEUMATIC DISEASES

Discussion

The results of this study confirm the observations that the serum sulphydryl content is low in patients with rheumatoid arthritis, that it can be raised by the administration of penicillamine, and that this is associated with a fall in rheumatoid factor titre. Before this elevation of serum sulphydryl content by penicillamine could be accepted as a possible mechanism of action of the drug, however, further studies with other thiol compounds appeared warranted in order to determine if there was any specificity to the penicillamine response. The other drugs were evaluated therefore with particular regard to their ability to increase the serum sulphydryl levels, and the effect, if any, of this increase upon the titre.

The data presented in the Table show that both N-acetyl D-penicillamine and mercaptoethylamine produced a rise in serum sulphydryl content comparable to that achieved with penicillamine within the same length of time. The virtual absence of sulphydryl groups in the ultrafiltrates of serum obtained during treatment with all the drugs indicates that, in each instance, the sulphydryl was protein-bound. The failure of both N-acetyl D-penicillamine and mercaptoethylamine to produce a fall in titre is evidence that the elevation of the serum protein sulphydryl content is not per se responsible for the reduction in titre produced by penicillamine. This is in keeping with the fact that a depressed serum sulphydryl concentration is not a finding unique to the rheumatoid patient or to patients with other forms of macroglobulinaemia, but is found in many systemic diseases associated with serum protein abnormalities (Schoenbach, Weissman, and Armistead, 1951).

The particular molecular configuration of penicillamine must be required for certain specific sulphydryl interactions in vivo, either directly on proteins or on protein synthesis. Alternatively, the drug might affect serum proteins primarily because of its metal-binding properties, the rise in serum sulphydryl content merely reflecting the absorption of this or any other systemically administered thiol compound. Acetyl penicillamine has a different spectrum of chelation from that of penicillamine (Aposhian, 1960; Scheinberg, 1964), and mercaptoethylamine has not been demonstrated to be a chelating agent in vivo. Since copper and other divalent cations are essential as co-factors in many enzymatic reactions required for protein (antibody) synthesis, depletion of a trace metal or its binding at the cellular level might be expected to be inhibitory.

It is possible that the effect of penicillamine administration on rheumatoid factor and its reported efficacy in other forms of macroglobulinaemia (Ritzmann, Coleman, and Levin, 1960; Edwards and Gengozian, 1965; Costanzi, Coltman, Clark, Tennenbaum, and Crisculo, 1965) share a common mechanism. Although penicillamine therapy was tried in such cases in an attempt to produce the intravascular dissociation of macroglobulins that can be accomplished in vitro by increasing the number of available sulphydryl groups (Ritzmann and others, 1960), the persistence of reduced macroglobulin levels for long periods after the drug was withdrawn has led several authors to question that this is the in vivo mechanism (Edwards and Gengozian, 1965; Costanzi and others, 1965). A similar pattern of response has been an almost constant finding in the arthritis patients, in whom there has been a sustained reduction in rheumatoid factor titre for many months after the termination

---

Fig. 3.—Comparison of D-penicillamine and N-acetyl D-penicillamine in a second patient. Again, only D-penicillamine was effective in lowering the titre, while the post-treatment sulphydryl concentrations in the serum were comparable for both drugs.
of the penicillamine therapy (Jaffe, 1963, 1965). This is illustrated by Patient 1 (Fig. 2), whose titre failed to return to its previous control level (8/2/66 and 9/12/65) many months after the first course of penicillamine was completed and the serum sulphydryl content had again fallen.

It is concluded that the mechanism of the in vivo effect of penicillamine on the rheumatoid factor, and perhaps on other macroglobulins as well, remains to be elucidated. Since penicillamine is a drug with many well-defined and diverse pharmacological properties, extrapolation from in vitro systems may be misleading. The failure of two other thiol compounds to induce a fall in rheumatoid factor titre while they significantly raised the serum protein sulphydryl content, and the lack of specificity of this biochemical abnormality for rheumatoid arthritis and other forms of macroglobulinaemia, suggests that this is not the mechanism of action of the drug.

**Summary**

The serum sulphydryl content was measured weekly in two patients with rheumatoid arthritis who were treated with three sulphydryl compounds: D-penicillamine, N-acetyl D-penicillamine, and mercaptopethylamine. All these drugs produced a comparable increase in serum protein sulphydryl content within the same length of time. Rheumatoid factor titre fell, however, only during D-penicillamine administration. It is concluded that increasing the serum sulphydryl content is not the mechanism by which penicillamine produces a fall in rheumatoid factor titre. The particular sulphydryl reactivity of the penicillamine molecule or its specific chelating properties may be responsible for the effect of penicillamine on the titre in vivo.

The D-penicillamine and N-acetyl D-penicillamine was provided by Dr. Elmer Alpert, Merck Sharp and Dohme Research Laboratories, West Point, Pa.

**REFERENCES**


L'effet de l'augmentation du taux sérique de sulfhydryl sur le titre du facteur rhumatoïde

Résumé
On dosa chaque semaine le taux de sulfhydryl sérique des malades ayant une polyartrite rhumatoïde traitées par trois composés sulfhydrés: D-penicillamine, N-acétyl D-penicillamine et mercaptoéthylamine. Tous ces produits provoquèrent une augmentation comparable du taux de sulfhydryl des protéines sériques dans les mêmes délais. Le titre du facteur rhumatoïde cependant ne baissa que lors de l'administration de D-penicillamine. On en conclut que l'augmentation du taux du sulfhydryl sérique n'est pas le mécanisme par lequel la pénicillamine entraîne une baisse du titre du facteur rhumatoïde. La réactivité particulière du sulfhydryl de la molécule de la pénicillamine ou ses propriétés spécifiques de chélateur peuvent être responsables de l'effet de la pénicillamine sur le titre in vivo.

El efecto de las cifras aumentadas de sulfhidril en el suero sobre el título del factor reumatoide

SUMARIO
Se determinó una vez por semana la tasa del sulfhidril sérico en enfermos con artritis reumatoide tratados con tres compuestos de sulfhidril: D-penicillamina, N-acetil D-penicillamina y mercaptoetilamina. Todos estos compuestos produjeron un aumento comparable de las cifras del sulfhidril de las proteínas séricas al cabo de un período similar. Las cifras del factor reumatoide bajaron sólo con la administración de D-penicillamina. Se concluye que la aumentación del contenido de sulfhidril en el suero no es el mecanismo mediante el cual la penicillamina produce una baja del título del factor reumatoide. La reactividad particular del sulfhidril de la molécula de la penicillamina o sus propiedades queladoras específicas pueden ser responsables del efecto de la penicillamina sobre el título in vivo.
Effect of increased serum sulphydryl content on titre of rheumatoid factor.
I A Jaffe and P Merryman

*Ann Rheum Dis* 1968 27: 14-18
doi: 10.1136/ard.27.1.14

Updated information and services can be found at:
http://ard.bmj.com/content/27/1/14.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/